(Q40216635)

18 September 2017

title

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial (English)

1 reference

18 September 2017

main subject

phase III clinical trial

0 references

0 references

1 reference

1

Adriana H Tremoulet

1 reference

18 September 2017

Sonia Jain

2

1 reference

18 September 2017

Preeti Jaggi

3

1 reference

18 September 2017

Susan Jimenez-Fernandez

4

1 reference

18 September 2017

Joan M Pancheri

5

1 reference

18 September 2017

Xiaoying Sun

6

1 reference

18 September 2017

John T Kanegaye

7

1 reference

18 September 2017

John P Kovalchin

8

1 reference

18 September 2017

Beth F Printz

9

1 reference

18 September 2017

Octavio Ramilo

10

1 reference

18 September 2017

Jane C Burns

11

1 reference

18 September 2017

language of work or name

English

0 references

publication date

24 February 2014

1 reference

18 September 2017

1 reference

18 September 2017

volume

383

1 reference

18 September 2017

issue

9930

1 reference

18 September 2017

page(s)

1731-1738

1 reference

Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Resistance to intravenous immunoglobulin in children with Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Infliximab treatment for refractory Kawasaki syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Diagnosis, treatment, and long-term management of Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Predictors of coronary artery visualization in Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Coronary artery dimensions may be misclassified as normal in Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Marked variations in serial coronary artery diameter measures in Kawasaki disease: a new indicator of coronary involvement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Infliximab for Kawasaki syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Infliximab treatment for refractory kawasaki disease in korean children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962298-9

7 January 2021

10.1016/S0140-6736(13)62298-9

Identifiers

DOI

1 reference

18 September 2017

1 reference